Phio Pharmaceuticals Corp (PHIO)

[sidslids]

10q

"Since inception, we have incurred significant losses. Substantially all of our losses to date have resulted from research and development expenses in connection with our clinical and research programs and from general administrative costs. At September 30, 2016, we had an accumulated deficit of $63.8 million. We expect to continue to incur significant losses for the foreseeable future, particularly as we advance our development programs for RXI-109 and Samcyprone™."


it is listed under liabilities and stockholders' equity

Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued or outstanding
— —
Common stock, $0.0001 par value, 100,000,000 shares authorized; 6,599,846 and 6,534,846 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively

Sep 2016.........Dec 2015
66,795.............65,994-------Additional paid-in capital
(63,760).........(57,105)-------Accumulated deficit
3,036.................8,890-------Total stockholders’ equity